Inogen, Inc. Expected to Post Q1 2023 Earnings of ($0.61) Per Share (NASDAQ:INGN)

Inogen, Inc. (NASDAQ:INGNGet Rating) – Analysts at William Blair dropped their Q1 2023 earnings per share estimates for Inogen in a research note issued to investors on Tuesday, February 28th. William Blair analyst M. Kaczor now forecasts that the medical technology company will post earnings per share of ($0.61) for the quarter, down from their prior estimate of ($0.54). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Inogen’s current full-year earnings is ($2.25) per share. William Blair also issued estimates for Inogen’s Q2 2023 earnings at ($0.47) EPS, Q3 2023 earnings at ($0.38) EPS, Q4 2023 earnings at ($0.31) EPS, FY2023 earnings at ($1.78) EPS, Q1 2024 earnings at ($0.26) EPS, Q2 2024 earnings at ($0.18) EPS, Q3 2024 earnings at ($0.22) EPS and Q4 2024 earnings at ($0.32) EPS.

Several other research analysts have also recently weighed in on INGN. Needham & Company LLC reduced their price target on Inogen from $36.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, February 24th. JPMorgan Chase & Co. reduced their price target on Inogen from $32.00 to $22.00 and set a “neutral” rating for the company in a research report on Thursday, November 3rd. Three analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $26.00.

Inogen Stock Up 1.0 %

Shares of NASDAQ:INGN opened at $15.71 on Thursday. Inogen has a 52-week low of $14.51 and a 52-week high of $35.67. The stock has a market cap of $360.86 million, a price-to-earnings ratio of -4.25 and a beta of 1.05. The business has a 50-day moving average price of $21.96 and a 200-day moving average price of $23.27.

Inogen (NASDAQ:INGNGet Rating) last released its quarterly earnings results on Thursday, February 23rd. The medical technology company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.03. Inogen had a negative return on equity of 8.72% and a negative net margin of 22.21%. The company had revenue of $88.09 million during the quarter, compared to analysts’ expectations of $89.70 million. During the same period last year, the business posted ($1.01) earnings per share. The firm’s revenue was up 15.3% compared to the same quarter last year.

Institutional Trading of Inogen

Institutional investors have recently made changes to their positions in the company. Yousif Capital Management LLC boosted its stake in shares of Inogen by 9.2% in the third quarter. Yousif Capital Management LLC now owns 18,575 shares of the medical technology company’s stock worth $451,000 after acquiring an additional 1,570 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Inogen by 383.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,270 shares of the medical technology company’s stock worth $55,000 after buying an additional 1,800 shares during the last quarter. Texas Permanent School Fund boosted its stake in Inogen by 10.9% during the third quarter. Texas Permanent School Fund now owns 16,364 shares of the medical technology company’s stock worth $397,000 after buying an additional 1,602 shares during the last quarter. Landscape Capital Management L.L.C. boosted its stake in Inogen by 18.3% during the second quarter. Landscape Capital Management L.L.C. now owns 53,097 shares of the medical technology company’s stock worth $1,284,000 after buying an additional 8,226 shares during the last quarter. Finally, Truist Financial Corp boosted its stake in Inogen by 92.3% during the third quarter. Truist Financial Corp now owns 24,200 shares of the medical technology company’s stock worth $587,000 after buying an additional 11,617 shares during the last quarter. 95.93% of the stock is owned by institutional investors and hedge funds.

About Inogen

(Get Rating)

Inogen, Inc engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home.

Read More

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.